Lipoprotein(a) and Cardiovascular Risk: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Lipoprotein(a) [Lp(a)] has emerged as a significant, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are genetically determined and confer increased risk for coronary artery disease, stroke, and aortic valve stenosis. Despite advances in lipid-lowering therapies, Lp(a)-mediated risk remains largely unaddressed by conventional treatments. This review synthesizes current epidemiological data, explores the molecular mechanisms underpinning Lp(a)'s atherogenicity, discusses clinical relevance, diagnostic strategies, and examines established and emerging therapies targeting Lp(a), with a focus on recent guideline recommendations and future directions for Lp(a)-modifying interventions.

Introduction

Lipoprotein(a) is a cholesterol-rich lipoprotein particle structurally similar to low-density lipoprotein (LDL), distinguished by the presence of apolipoprotein(a) [apo(a)] covalently linked to apolipoprotein B-100 (apoB-100). Interest in Lp(a) has surged following robust evidence linking elevated plasma concentrations to increased ASCVD risk independent of traditional lipid parameters. However, Lp(a) remains underappreciated in routine clinical practice, partly due to historical limitations in assay standardization and therapeutic options. This review aims to provide clinicians and researchers with an evidence-based update on Lp(a), encompassing its epidemiology, pathophysiology, clinical implications, diagnostic strategies, and evolving therapeutic landscape.

Epidemiology / Disease Burden

The distribution of Lp(a) concentrations is highly variable and largely genetically determined, with inter-individual levels varying up to 1000-fold. Approximately 20% of the global population have Lp(a) levels exceeding 50 mg/dL, a threshold associated with marked cardiovascular risk. Epidemiological studies, including large-scale Mendelian randomization analyses, have established a causal relationship between elevated Lp(a) and ASCVD, independent of LDL cholesterol. Notably, certain ethnic groups, such as individuals of African descent, exhibit higher median Lp(a) concentrations, underscoring the need for population-specific risk stratification. The disease burden attributable to elevated Lp(a) is substantial, with estimates suggesting that up to 10% of premature myocardial infarctions in Western populations may be linked to high Lp(a) levels.

Pathophysiology

Lp(a) exerts its proatherogenic and prothrombotic effects via multiple mechanisms. The apo(a) moiety shares structural homology with plasminogen, thereby interfering with fibrinolysis and promoting thrombosis. Lp(a) particles are enriched in oxidized phospholipids, which are potent mediators of vascular inflammation, endothelial dysfunction, and atherogenesis. Additionally, Lp(a) facilitates foam cell formation, smooth muscle cell proliferation, and deposition within the arterial intima. These combined effects accelerate plaque development, instability, and calcification, contributing not only to coronary heart disease but also to calcific aortic valve disease.

Risk Factors

Elevated Lp(a) is primarily inherited in an autosomal codominant manner, with plasma concentrations largely determined by the LPA gene, particularly the number of kringle IV type 2 repeats. Secondary factors, such as chronic kidney disease, nephrotic syndrome, and certain inflammatory states, may further elevate Lp(a). Unlike other lipid fractions, Lp(a) is minimally influenced by diet, exercise, or most conventional pharmacotherapies. The presence of additional risk factors such as hypertension, diabetes, smoking, and familial hypercholesterolemia can synergistically amplify ASCVD risk when combined with elevated Lp(a) levels.

Clinical Features

Elevated Lp(a) is clinically silent and does not manifest with specific symptoms. Its relevance emerges in the context of premature ASCVD, unexplained myocardial infarction, recurrent atherosclerotic events despite optimal LDL-C lowering, and in individuals with a family history of early cardiac or cerebrovascular disease. Lp(a) is increasingly recognized as a contributor to calcific aortic valve stenosis, with observational studies demonstrating a graded association between Lp(a) levels and incident valve disease.

Diagnosis

Lp(a) measurement is recommended at least once in adulthood for cardiovascular risk stratification, particularly in individuals with premature ASCVD or a family history of early cardiovascular events. Assays should ideally report Lp(a) concentrations in nmol/L, as mass-based measurements (mg/dL) may be confounded by apo(a) isoform size heterogeneity. Clinical laboratories must utilize isoform-insensitive assays to ensure accuracy. Interpretation of Lp(a) levels is context-dependent, but values above 50 mg/dL (or ≥125 nmol/L) are generally considered high risk, warranting intensified preventive efforts.

Treatment & Management

Current management of elevated Lp(a) focuses primarily on aggressive modification of concomitant risk factors, including LDL-C lowering with statins, ezetimibe, and PCSK9 inhibitors, blood pressure control, and lifestyle optimization. Statins have negligible impact on Lp(a) levels, and some evidence suggests a modest increase. PCSK9 inhibitors can reduce Lp(a) by approximately 20–30%, with clinical trials indicating reductions in ASCVD events proportional to Lp(a) lowering. Lipoprotein apheresis remains a therapeutic option for individuals with very high Lp(a) and progressive ASCVD despite maximal medical therapy, though availability is limited. Niacin can lower Lp(a) by up to 30%, but its use is limited by tolerability and lack of demonstrated cardiovascular benefit in contemporary trials.

Recent Advances / Emerging Therapies

Recent years have witnessed the advent of novel RNA-targeted therapies specifically designed to lower Lp(a). Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting the LPA gene have demonstrated profound Lp(a) reductions (>80%) in phase II trials. Pelacarsen (an ASO) and olpasiran (a siRNA) are currently undergoing phase III trials to assess their impact on hard cardiovascular outcomes. These agents hold promise for transforming the management of Lp(a)-mediated risk, particularly in high-risk populations. Early data suggest favorable safety profiles, though long-term efficacy and safety remain to be established. The ongoing research landscape is rapidly evolving, with additional agents and combination strategies under development.

Guideline Recommendations

International guidelines, including those from the European Society of Cardiology (ESC) and American Heart Association (AHA), now recognize Lp(a) as a significant, genetically determined ASCVD risk factor. Both recommend a one-time Lp(a) measurement in adulthood to guide risk stratification, particularly in cases of premature ASCVD or strong family history. Individuals with elevated Lp(a) should receive intensified management of all modifiable risk factors. At present, no specific Lp(a)-targeted therapy has received widespread approval for cardiovascular risk reduction, though emerging therapies are anticipated to change practice paradigms in the near future.

Conclusion

Lipoprotein(a) represents a pivotal, independent determinant of cardiovascular risk. Its pathogenicity is mediated through complex proatherogenic and prothrombotic mechanisms, with substantial implications for both primary and secondary prevention. While current management emphasizes aggressive control of traditional risk factors, the imminent arrival of targeted Lp(a)-lowering therapies promises to fill a longstanding therapeutic gap. Routine assessment and recognition of Lp(a) in clinical practice are crucial for optimal risk stratification and the prevention of adverse cardiovascular outcomes in at-risk individuals.